28 May, 2017
Mufg Americas Holdings Corp increased Edwards Lifesciences Corp (EW) stake by 401.12% reported in 2016Q4 SEC filing. The rating was maintained by Barclays Capital with "Equalweight" on Wednesday, July 27. Sands Capital Management Llc sold 708,299 shares as Edwards Lifesciences Corp (EW)'s stock rose 25.80%. The shares were sold at an average price of $89.63, for a total transaction of $4,400,833.00. Edwards Lifesciences Corp now has $24.11B valuation. BlackRock Inc. raised its position in shares of Edwards Lifesciences Corp by 2,184.9% in the first quarter. The stock declined 0.82% or $0.94 reaching $113.15 on the news. The stock has a market capitalization of $23.94 billion, a PE ratio of 37.93 and a beta of 0.53. The stock was sold at an average price of $90.01, for a total transaction of $1,234,937.20. The Trellus Management Company Llc holds 15,000 shares with $1.41M value, up from 7,700 last quarter. After $0.94 actual EPS reported by Edwards Lifesciences Corp for the previous quarter, Wall Street now forecasts -6.38% negative EPS growth. Edwards Lifesciences Corp has a 52 week low of $81.12 and a 52 week high of $121.75. Seven Bridges Advisors LLC increased its stake in Edwards Lifesciences Corp by 1.0% in the third quarter. The stock's 50-day moving average price is $104.97 and its 200-day moving average price is $95.34. Edwards Lifesciences Corp had a return on equity of 25.00% and a net margin of 19.22%. With 492,300 avg volume, 5 days are for Kraton Corporation (NYSE:KRA)'s short sellers to cover KRA's short positions. Marshall Wace LLP now owns 713,323 shares of the medical research company's stock valued at $66,839,000 after buying an additional 699,998 shares in the last quarter.
Several equities analysts have issued reports on the company. The firm had revenue of $883.50 million during the quarter, compared to the consensus estimate of $776.51 million. Vetr cut Edwards Lifesciences Corp from a "strong-buy" rating to a "buy" rating and set a $124.67 target price for the company.in a report on Monday. Can now owns 153,173 shares of the medical research company's stock worth $18,449,000 after buying an additional 2,931 shares during the period.
ILLEGAL ACTIVITY NOTICE: "Edwards Lifesciences Corp (EW) Updates Q2 Earnings Guidance" was published by Markets Daily and is the property of of Markets Daily.
Edwards Lifesciences Corp (NYSE:EW) last posted its quarterly earnings results on Tuesday, April 25th. Citigroup initiated Edwards Lifesciences Corp (NYSE:EW) on Thursday, November 12 with "Sell" rating.
Several hedge funds and other institutional investors have recently bought and sold shares of EW. Quadrant Capital Group LLC boosted its stake in shares of Edwards Lifesciences Corp by 3.5% in the first quarter. Analysts predict that Edwards Lifesciences Corp will post $3.53 EPS for the current year. The stock of Edwards Lifesciences Corp (NYSE:EW) has "Buy" rating given on Wednesday, April 26 by Stifel Nicolaus. The firm has "Mkt Perform" rating given on Wednesday, January 6 by JMP Securities. Ltd. increased its position in Edwards Lifesciences Corp by 17.6% in the third quarter. If you are accessing this article on another website, it was illegally copied and reposted in violation of USA and global trademark & copyright legislation. As per Monday, August 10, the company rating was reinitiated by Credit Suisse. Financial Architects Inc now owns 2,820 shares of the medical research company's stock worth $340,000 after buying an additional 1,123 shares during the period. The company was initiated on Tuesday, September 22 by UBS. The disclosure for this sale can be found here. Finally, Marshall Wace North America L.P. acquired a new position in Edwards Lifesciences Corp during the first quarter worth $126,959,000. Also, CEO Michael A. Mussallem sold 49,100 shares of the firm's stock in a transaction dated Friday, April 28th. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 12,257 shares of the medical research company's stock worth $1,148,000 after buying an additional 99 shares in the last quarter.
Edwards Lifesciences Corporation is a maker of heart valve systems and fix products used to replace or fix a patient's diseased or defective heart valve. The Firm is engaged in patient-focused innovations for structural heart disease and critical care monitoring. The Company's MicroCutter 5/80 is a commercially available cartridge microcutter device with approximately five millimeter shaft diameter, over 80 degrees of articulation, and an approximately 30 millimeter staple line cleared for specified indications for use in the United States, and in the European Union for a range of indications for use.